Gut metabolite butyrate eases TMJ pain in mouse study

By AI, Created 5:43 AM UTC, May 18, 2026, /AGP/ – Researchers at Texas A&M University report that the gut microbiome metabolite butyrate reduced inflammatory temporomandibular joint pain in mice by restoring epigenetic marks and gene regulation in the brain. The findings, published April 17, 2026, point to a possible non-opioid approach for chronic orofacial pain.

Why it matters: - Temporomandibular joint pain is a major cause of chronic orofacial pain, and current treatment options remain limited. - The study points to a non-opioid pathway for treating TMJ pain by targeting gut-microbiome-related metabolites and brain epigenetics. - The work suggests that butyrate-related therapies could inform future treatment for chronic pain conditions beyond TMJ disorders.

What happened: - A Texas A&M University research team led by Drs. Sufang Liu and Feng Tao studied inflammatory TMJ pain in mice. - The study was published in the International Journal of Oral Science on April 17, 2026. - Researchers tested tributyrin, a prodrug that releases butyrate, and found that oral treatment reduced TMJ pain. - Tributyrin also restored butyrate levels in the gut, blood and spinal trigeminal nucleus caudalis, or Sp5C.

The details: - The team used single-cell multi-omics sequencing, combining single-nucleus RNA sequencing and chromatin accessibility profiling, to study the Sp5C. - Researchers identified 12 cell types, including neuronal and glial populations. - TMJ pain changed gene expression and chromatin accessibility across those cell types without changing overall cellular composition. - The pain condition disrupted regulation of genes including Nop14, Matk, Idh3b, Ndst2 and Tomm6. - Tributyrin reversed those gene-level changes and restored regulation toward normal levels. - TMJ pain was linked to reduced histone acetylation in the Sp5C. - Tributyrin restored histone acetylation and normalized acetylation- and deacetylation-related genes across cell types. - Nop14 stood out as a key regulator. - TMJ pain increased Nop14 expression and chromatin accessibility, while tributyrin reversed both effects. - Knockdown of Nop14 in the Sp5C restored histone acetylation and significantly reduced pain in mice. - The paper’s DOI is https://doi.org/10.1038/s41368-026-00432-9.

Between the lines: - The study ties a gut-derived metabolite to pain control through cell-type-specific changes in the central nervous system. - The findings suggest that TMJ pain is driven by coordinated transcriptional and epigenetic shifts, not just inflammation alone. - Dr. Liu said, “Five key genes showed consistent regulatory changes in TMJ pain and were restored by tributyrin.” - Dr. Tao said, “Nop14 could be targeted to develop a novel therapy for TMJ pain.”

What’s next: - The results need follow-up work before any human treatment can be considered. - Researchers are likely to test whether butyrate-related epigenetic pathways can be translated into safer pain therapies. - Future studies may also examine whether Nop14 or related gene networks can serve as drug targets for chronic orofacial pain.

The bottom line: - Butyrate and its derivatives may offer a new non-opioid route to ease TMJ pain by reversing epigenetic changes in pain-processing brain regions.